FMS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
FMS vs MRK: Head-to-Head Comparison
This page compares Fresenius Medical Care AG (FMS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.